ADMA Biologics Inc (ADMA) Stock Analysis

Verdict: WATCH (do not buy)

Guidance cuts and flat Q1 revenue have broken the growth narrative, turning a high-margin compounder into a 'show-me' value trap.

Investment score: 44/100

Analysis as of 2026-06-03

Is ADMA Biologics Inc stock worth reviewing? AI model thesis

ADMA is currently a falling knife with strong fundamentals. While it appears 'cheap' relative to peers like SRPT, the momentum is toxic following guidance downgrades.

7-factor investment score

Valuation: 72/100 (weight 20%)
Financial Health: 85/100 (weight 15%)
Technical Momentum: 15/100 (weight 15%)
Earnings Quality: 35/100 (weight 15%)
Insider Sentiment: 50/100 (weight 10%)
Analyst Consensus: 40/100 (weight 10%)
Risk-Adjusted Return: 30/100 (weight 15%)

ADMA Biologics Inc opportunities and risks

What speaks for ADMA

Compelling Valuation vs. Peers

What speaks against ADMA

Continued Growth Stagnation

Peers and competitors

Trailing-twelve-month ratios
Ticker	P/E	P/S	EV/EBITDA	Gross margin	Net margin	FCF yield
ADMA	10.9x	3.5x	8.6x	61.3%	32.4%	6.1%
STOK	n/a	56.0x	n/a	90.4%	-529.2%	-8.2%
IOVA	n/a	5.0x	n/a	114.5%	-123.9%	-21.4%
TYRA	n/a	0.0x	n/a	0.0%	0.0%	-5.8%
NTLA	n/a	21.7x	n/a	-31.9%	-597.0%	-25.4%
SRPT	26.4x	0.8x	18.4x	62.4%	3.0%	6.2%
Peer median	n/a	5.0x	n/a	62.4%	-123.9%	-8.2%

Frequently asked questions about ADMA Biologics Inc (ADMA)

Is ADMA stock a good investment?

The cached TradeMates AI model rates ADMA Biologics Inc as WATCH (do not buy) with an investment score of 44/100. ADMA is currently a falling knife with strong fundamentals. While it appears 'cheap' relative to peers like SRPT, the momentum is toxic following guidance downgrades. This is algorithmic model output, not personal investment advice.

Is ADMA stock a buy?

The TradeMates model verdict for ADMA is WATCH (do not buy) with an investment score of 44/100. Treat this as a model signal to review, not a personal buy recommendation.